“乙肝患者长期服用阿司匹林可降低肝癌风险”

StephenW

“乙肝患者长期服用阿司匹林可降低肝癌风险”

    기자명 Marianne Chang Published 2022.06.30 17:22

SNS 기사보내기

Severance 医院周四援引其研究人员最近的一项研究称，乙型肝炎患者长期服用阿司匹林可将肝癌和肝病相关死亡人数减少 16% 和 21%。
左起，Severance 医院的 Kim Beom-kyung 教授共同研究人员 Yoon Jin-ha 教授和延世大学医学院的 Yun Byung-yoon 讲师。
左起，Severance 医院的 Kim Beom-kyung 教授共同研究人员 Yoon Jin-ha 教授和延世大学医学院的 Yun Byung-yoon 讲师。

乙型肝炎由于乙型肝炎病毒 (HBV) 感染引起免疫反应，导致肝脏炎症。各种抗病毒药物已经被开发出来，但未能一起治疗，导致肝癌。阿司匹林已证明可降低慢性肝炎患者患肝癌的风险。然而，尚不清楚患者组的哪个特征导致了这种效果，也不清楚剂量或持续时间与降低风险的效果之间的关系。

该研究将 40 岁或以上的乙型肝炎患者分为服用阿司匹林 3 年以上的患者组（9837 例）和未服用阿司匹林组（151836 例），并比较了他们的肝癌平均发病率和肝病相关存活率。

在给药组和未给药组中，肝癌的平均年发病率分别为每 100,000 人 517 人和 568 人。

考虑到多种因素（年龄、性别、血压、糖尿病、肝硬化、乙型肝炎治疗、二甲双胍和他汀类药物的使用）的多变量分析表明，服用阿司匹林的组患肝癌和肝病的风险相对较低据医院称，与疾病相关的死亡人数分别为 16% 和 21%。

阿司匹林对个体代谢疾病和药物的影响表明，在肝硬化和高血压患者中长期使用阿司匹林可将患肝癌的风险分别显着降低 19% 和 14%。然而，在服用以预防癌症效果而闻名的二甲双胍和他汀类抗病毒药物的组中，它是无效的。

“以前的研究表明阿司匹林对肝癌有预防作用。然而，这项研究表明，不仅服用阿司匹林的效果，还应考虑个人代谢疾病和药物使用等因素，”金范京教授消化内科表示，“我们将进行更多研究，以揭示阿司匹林降低肝癌风险之间的关系，以提供个性化的患者治疗。”

该研究可在最新一期的美国胃肠病学杂志上获得。

StephenW

‘Hepatitis B patients can lower liver cancer risk by taking aspirin long term’

    기자명 Marianne Chang Published 2022.06.30 17:22

SNS 기사보내기

Long-term use of aspirin by hepatitis B patients can reduce liver cancer and liver disease-related deaths by 16 and 21 percent, Severance Hospital said Thursday, citing a recent study by its researchers.
From left, Professor Kim Beom-kyung of the Severance Hospital co-researchers Professor Yoon Jin-ha and Lecturer Yun Byung-yoon of Yonsei University College of Medicine.
From left, Professor Kim Beom-kyung of the Severance Hospital co-researchers Professor Yoon Jin-ha and Lecturer Yun Byung-yoon of Yonsei University College of Medicine.

Hepatitis B causes an immune reaction due to hepatitis B virus (HBV) infection, leading to liver inflammation. Various antiviral drugs have already been developed but failed to treat it all together, resulting in liver cancer. Aspirin has demonstrated a reduced risk of liver cancer in chronic hepatitis patients. However, it was unclear which characteristic of the patient group caused that effect nor the relationship between the dose or duration and the risk-reducing effects.

The research analyzed hepatitis B patients 40 years or older into a group of patients (9,837) administered with aspirin for more than three years and the unadministered group (151,836) and compared their average incidence of liver cancer and liver disease-related survival rate.

The average annual incidence of liver cancer was 517 and 568 people per 100,000 in the administered and unadministered groups.

The multivariate analysis considering a wide variety of factors -- age, gender, blood pressure, diabetes, cirrhosis, hepatitis B treatment, metformin, and statin use -- demonstrated that the aspirin-administered group had a comparatively lower risk of liver cancer and liver disease-related deaths of 16 and 21 percent, according to the hospital.

The effect of aspirin on metabolic diseases and medications in individuals showed that long-term aspirin use in patients with cirrhosis and high blood pressure lowered significantly the risk of developing liver cancer by 19 and 14 percent, respectively. However, it was ineffective in the group taking the antiviral drugs of metformin and statins, well-known for their cancer prevention effects.

"Previous studies suggested the preventive effects of aspirin in liver cancer. However, this study indicates not just the effects of taking aspirin but also factors like metabolic diseases of individuals and the use of medications should be considered," Professor Kim Bum-kyung of the Department of Gastroenterology said, "We will conduct additional studies to reveal the relationship between aspirin's reduction in liver cancer risk to provide personalized patient treatment."

The study is available in the latest American Journal of Gastroenterology issue.

StephenW

关于阿司匹林的剂量和长期使用，请咨询您的医生!